Opendata, web and dolomites

UNPACK PD-L1 SIGNED

Molecular mechanism and inhibition of extracellular vesicle-mediated PD-L1 release in melanoma cells

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 UNPACK PD-L1 project word cloud

Explore the words cloud of the UNPACK PD-L1 project. It provides you a very rough idea of what is the project "UNPACK PD-L1" about.

limited    anti    druggable    broaden    reveal    clear    suppress    inhibiting    evs    intend    herein    sought    power    successful    membrane    mechanism    inhibit    responder    tested    plasma    oncological    systemic    lay    express    little    ideally    subsequent    programmed    tumor    bottlenecks    release    levels    types    plausible    treat    block    groundwork    therapies    extracellular    patients    inhibition    cell    checkpoint    stratify    molecular    direction    stage    therapy    small    pd    inhibitors    suppression    upregulation    cancer    tumorigenic    screen    drug    strategy    secretion    mechanisms    circulating    mediated    death    initiated    candidates    harnessing    loading    clinically    basic    exploited    tumour    clinical    therapeutic    vesicles    optical    highlighting    ligand    reporters    modality    function    surround    combining    models    ev    efficacy    blockade    drive    remove    guide    agents    center    secrete    cells    meant    gaps    vitro    pro    outcome    responders    bracket    bioluminescent    restore    immunosuppression    mouse    rationale    immune    l1    unanticipated    uncover    melanoma    receptor   

Project "UNPACK PD-L1" data sheet

The following table provides information about the project.

Coordinator
STICHTING VUMC 

Organization address
address: DE BOELELAAN 1117
city: AMSTERDAM
postcode: 1081 HV
website: www.vumc.nl

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Total cost 175˙572 €
 EC max contribution 175˙572 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2018
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2020
 Duration (year-month-day) from 2020-02-01   to  2022-01-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    STICHTING VUMC NL (AMSTERDAM) coordinator 175˙572.00

Map

 Project objective

Harnessing the power of the immune system to treat cancer has long been a sought after goal of oncological research. Immune checkpoint inhibitors, such as anti-programmed death receptor 1 (PD-1) blockade therapies, have now taken center stage. However not all patients respond, highlighting gaps in our understanding of the mechanisms of tumour immunosuppression. Upregulation of the PD-1 ligand (PD-L1) on tumour cells initiated this therapeutic direction, yet it is becoming clear that the modality of PD-L1-mediated immune suppression is not limited to the plasma membrane. Like many tumor cells, melanoma cells secrete small extracellular vesicles (EVs) with pro-tumorigenic properties. Melanoma EVs express PD-L1 that suppress T cell function and facilitate tumour growth in pre-clinical mouse models. This systemic mechanism is clinically relevant, as circulating EV-PD-L1 levels can stratify anti-PD-1 clinical responders from non-responders. Thus inhibiting EV-PD-L1 may increase anti-PD-1 efficacy and broaden the responder bracket. One plausible strategy would be to block tumor EV secretion, yet little is known about the molecular mechanisms that drive PD-L1 loading and release. Herein, I intend to uncover the molecular mechanisms of EV PD-L1 release from melanoma cells using state-of-the-art optical and bioluminescent reporters to reveal novel druggable targets. This basic knowledge will be exploited to guide subsequent inhibition, through a drug screen for candidates that inhibit EV-PD-L1 release and restore T cell function. Ideally the outcome of this in vitro study will provide a strong rationale for combining anti-PD-1 agents with inhibitors of EV-PD-L1 secretion, to be tested in pre-clinical mouse models. If successful, melanoma EV blockade may remove the unanticipated bottlenecks that surround the efficacy of anti-PD-1 therapy. In the long term this study is meant to lay groundwork for tumor EV inhibition as a therapeutic strategy for cancer types beyond melanoma.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "UNPACK PD-L1" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "UNPACK PD-L1" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

COLEX (2019)

Coopetition and Legislation in the Spanish Netherlands (1598-1665)

Read More  

iRhomADAM (2020)

Uncovering the role of the iRhom2-ADAM17 interaction in inflammatory signalling

Read More  

NPsVLCD (2019)

Natural Product-Inspired Therapies for Leishmaniasis and Chagas Disease

Read More